(RTTNews) - Myriad Genetics, Inc. (MYGN) on Tuesday reported first-quarter results with revenue rising slightly from last year, while losses widened compared to the prior period.
The company posted revenue of $200.4 million for the three months ended March 31, 2026, up from $195.9 million a year earlier. Net loss widened to $34.1 million from a near break-even loss of $0.1 million in the prior-year quarter. Loss per share was $0.36 for the quarter, while weighted average shares outstanding stood at 93.7 million.
Operating loss came in at $30.7 million, up from $29.0 million last year, as total operating expenses increased to $168.3 million from $163.2 million. The higher expenses were driven in part by research and development costs of $27.1 million and sales and marketing expenses of $73.6 million.
MYGN is currently trading after hours at $4.47, down $0.56 or 11.13 percent on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
